When deciding whether to roll out a new mass screening programme (for example, for diseases such as prostate cancer), the benefits must be weighed against the costs of the test, the risks of taking the test, and cost to people who receive a positive result, and must undergo further invasive, stressful and possible risky testing, even if they do not actually have the cancer.